Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Non-Current Liabilities (2022 - 2025)

Vivos Therapeutics' Total Non-Current Liabilities history spans 3 years, with the latest figure at $25.4 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $25.4 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $25.4 million (changed N/A YoY), and the annual figure for FY2025 was $25.4 million, changed.
  • Total Non-Current Liabilities for Q4 2025 was $25.4 million at Vivos Therapeutics, up from $21.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $25.4 million in Q4 2025 to a low of $8.4 million in Q1 2022.
  • The 3-year median for Total Non-Current Liabilities is $9.7 million (2023), against an average of $14.8 million.
  • Peak annual rise in Total Non-Current Liabilities hit 4.17% in 2023, while the deepest fall reached 4.17% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $8.4 million in 2022, then rose by 15.26% to $9.7 million in 2023, then soared by 161.88% to $25.4 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $25.4 million, $21.7 million, and $20.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.